Literature DB >> 1727485

Pathogenesis of early and late disease in mice infected with Theiler's virus, using intratypic recombinant GDVII/DA viruses.

M Rodriguez1, R P Roos.   

Abstract

Intratypic recombinant Theiler's viruses prepared between GDVII and DA strains were used to identify genomic sequences important in neurovirulence, virus persistence, and demyelination and to clarify the mechanisms involved in disease induction. The coding region between 1B and 2C of the highly virulent GDVII strain contains a determinant partly responsible for neurovirulence (early paralysis and death) which correlates with elevated levels of infectious virus and the presence of virus antigen within neurons of the brain stem and gray matter of the spinal cord. Both the GDVII and the DA strains of virus contain genetic determinants for late demyelination in spinal cord. However, quantitative analysis of demyelination produced by recombinant GDVII/DA viruses suggest that multiple gene segments influence the number and extent of demyelinating lesions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1727485      PMCID: PMC238278     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Molecular cloning of the complete genome of strain GDVII of Theiler's virus and production of infectious transcripts.

Authors:  F Tangy; A McAllister; M Brahic
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

2.  Replication of Theiler's murine encephalomyelitis viruses in BHK21 cells: an electron microscopic study.

Authors:  A Friedmann; H L Lipton
Journal:  Virology       Date:  1980-03       Impact factor: 3.616

3.  A neutralization-resistant Theiler's virus variant produces an altered disease pattern in the mouse central nervous system.

Authors:  A Zurbriggen; R S Fujinami
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

4.  Genomic regions of neurovirulence and attenuation in Theiler murine encephalomyelitis virus.

Authors:  M A Calenoff; K S Faaberg; H L Lipton
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

5.  Genetic mapping of the ability of Theiler's virus to persist and demyelinate.

Authors:  A McAllister; F Tangy; C Aubert; M Brahic
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

6.  Neurovirulence determinants of genetically engineered Theiler viruses.

Authors:  J L Fu; S Stein; L Rosenstein; T Bodwell; M Routbort; B L Semler; R P Roos
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

7.  Molecular cloning of the complete genome of Theiler's virus, strain DA, and production of infectious transcripts.

Authors:  A McAllister; F Tangy; C Aubert; M Brahic
Journal:  Microb Pathog       Date:  1989-11       Impact factor: 3.738

8.  Analysis of Theiler's virus isolates from persistently infected mouse nervous tissue.

Authors:  R P Roos; O C Richards; E Ehrenfeld
Journal:  J Gen Virol       Date:  1983-03       Impact factor: 3.891

9.  Theiler's murine encephalomyelitis virus group includes two distinct genetic subgroups that differ pathologically and biologically.

Authors:  Y Lorch; A Friedmann; H L Lipton; M Kotler
Journal:  J Virol       Date:  1981-11       Impact factor: 5.103

10.  Persistent infection of oligodendrocytes in Theiler's virus-induced encephalomyelitis.

Authors:  M Rodriguez; J L Leibowitz; P W Lampert
Journal:  Ann Neurol       Date:  1983-04       Impact factor: 10.422

View more
  18 in total

1.  Influence of the Theiler's virus L* protein on macrophage infection, viral persistence, and neurovirulence.

Authors:  O van Eyll; T Michiels
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

2.  Different strains of Theiler's murine encephalomyelitis virus antagonize different sites in the type I interferon pathway.

Authors:  Spyridon Stavrou; Zongdi Feng; Stanley M Lemon; Raymond P Roos
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

3.  The neurovirulence of the DA and GDVII strains of Theiler's virus correlates with their ability To infect cultured neurons.

Authors:  N Jarousse; S Syan; C Martinat; M Brahic
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

4.  The immune system preferentially clears Theiler's virus from the gray matter of the central nervous system.

Authors:  M K Njenga; K Asakura; S F Hunter; P Wettstein; L R Pease; M Rodriguez
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

5.  Mouse neuropathogenic poliovirus strains cause damage in the central nervous system distinct from poliomyelitis.

Authors:  M Gromeier; H H Lu; E Wimmer
Journal:  Microb Pathog       Date:  1995-04       Impact factor: 3.738

6.  Three-dimensional structure of Theiler virus.

Authors:  R A Grant; D J Filman; R S Fujinami; J P Icenogle; J M Hogle
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

7.  An infectious cDNA copy of the genome of a non-cardiovirulent coxsackievirus B3 strain: its complete sequence analysis and comparison to the genomes of cardiovirulent coxsackieviruses.

Authors:  N M Chapman; Z Tu; S Tracy; C J Gauntt
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

8.  An attenuated variant of the GDVII strain of Theiler's virus does not persist and does not infect the white matter of the central nervous system.

Authors:  N Jarousse; E G Viktorova; E V Pilipenko; V I Agol; M Brahic
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

Review 9.  Theiler's virus infection: a model for multiple sclerosis.

Authors:  Emilia L Oleszak; J Robert Chang; Herman Friedman; Christos D Katsetos; Chris D Platsoucas
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

10.  Theiler's murine encephalomyelitis virus L* amino acid position 93 is important for virus persistence and virus-induced demyelination.

Authors:  Spyridon Stavrou; Gleb Baida; Ekaterina Viktorova; Ghanashyam Ghadge; Vadim I Agol; Raymond P Roos
Journal:  J Virol       Date:  2009-11-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.